Further Modifying the Scope of Products of Canada Subject to the Additional Duties Imposed To Offset Canadian Discrimination Against the Commerce of the United States With Respect to Motor Vehicles

This is a Section 338 trade measure that modifies the scope of products from Canada subject to additional duties related to alleged discrimination against U.S. commerce involving motor vehicles. “Section 338” refers to a provision of U.S. trade law that can authorize additional duties or other import restrictions when foreign practices are considered discriminatory. The official measure controls; the title alone does not determine whether a product is covered.

It typically matters to importers of Canadian-origin motor vehicles, vehicle parts, or other products specifically identified by the measure. Coverage generally depends on the product’s Harmonized Tariff Schedule of the United States (HTSUS) classification, country of origin, any stated exclusions, and the applicable entry or importation rules. An affected product may require an additional duty reported separately from its ordinary tariff treatment, so incorrect classification or origin information can lead to entry corrections, unexpected costs, or compliance exposure.

What to check

• Read the measure’s operative scope and product descriptions, not just its title, and compare them with the applicable HTSUS provisions.
• Confirm the product’s tariff classification, including any parts or vehicle-specific provisions, with supporting technical information; seek a binding ruling or customs-broker advice when classification is uncertain.
• Verify country of origin under U.S. customs origin rules; shipping from Canada does not necessarily make a product Canadian-origin.
• Check the measure’s effective-entry rules, exclusions, exceptions, and any required reporting instructions in the official source before filing the entry.
• Ask your broker or trade-compliance professional to review whether the additional duty applies and to confirm the correct entry data and payment treatment.